Feb 24, 2021
|
Vertex to Present at the Cowen Health Care Conference on March 2
|
|
Feb 01, 2021
|
Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results
|
|
Jan 28, 2021
|
Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
|
|
Jan 26, 2021
|
Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
|
|
Jan 22, 2021
|
Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1
|
|
Jan 07, 2021
|
Vertex to Present at the J.P. Morgan Healthcare Conference on January 11
|
|
Dec 28, 2020
|
Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada
|
|
Dec 22, 2020
|
Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases
|
|
Dec 21, 2020
|
Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations
|
|
Dec 05, 2020
|
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine
|
|
Dec 01, 2020
|
CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Thalassemia
|
|
Nov 27, 2020
|
Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years
|
|
Nov 13, 2020
|
Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation
|
|
Nov 12, 2020
|
Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19
|
|
Nov 05, 2020
|
Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age
|
|
Nov 04, 2020
|
CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition
|
|
Oct 29, 2020
|
Vertex Reports Third-Quarter 2020 Financial Results
|
|
Oct 19, 2020
|
Vertex to Announce Third-Quarter 2020 Financial Results on October 29
|
|
Oct 14, 2020
|
Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency
|
|
Sep 25, 2020
|
FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
|
|